Immunocore Holdings plc (IMCR) Bundle
An Overview of Immunocore Holdings plc (IMCR)
General Summary of Immunocore Holdings plc
Immunocore Holdings plc (IMCR) was founded in 2008 and is headquartered in Abingdon, United Kingdom. The company specializes in developing innovative therapies for cancer and other diseases through its proprietary ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) platform. Its lead product, KIMMTRAK (tebentafusp), is designed to treat patients with metastatic uveal melanoma. As of 2024, Immunocore has expanded its portfolio and is advancing multiple clinical programs targeting various cancers and infectious diseases.
In 2024, Immunocore's total sales reached approximately $225.9 million for the nine months ended September 30, driven primarily by the sales of KIMMTRAK, which generated $162.9 million in the United States, $55.5 million in Europe, and $7.6 million internationally .
Company's Financial Performance in the Latest Financial Reports
Immunocore reported significant growth in its financial performance for the nine months ended September 30, 2024. The company achieved a total revenue of $226.2 million, reflecting a 26.2% increase compared to $179.3 million in the same period of 2023 . This increase was primarily attributed to the rise in product revenue, netting $225.9 million, up from $171.1 million year-over-year, marking a growth of 32.0%.
The following table summarizes key financial metrics for the nine months ended September 30, 2024, compared to the same period in 2023:
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $226.2 million | $179.3 million | $46.9 million (26.2%) |
| Product Revenue, net | $225.9 million | $171.1 million | $54.8 million (32.0%) |
| Net Income (Loss) | ($27.3 million) | ($35.6 million) | $8.3 million improvement |
| Cash and Cash Equivalents | $537.8 million | $442.6 million | $95.2 million increase |
Research and development (R&D) expenses for the same period totaled $161.3 million, an increase of 36.7% from $118.0 million in 2023, reflecting the company's commitment to advancing its clinical programs .
Introduction to Immunocore as a Leader in the Industry
Immunocore Holdings plc stands out as a leading player in the biotechnology sector, particularly in the immunotherapy space. The company's innovative approach to harnessing T-cell receptor technology positions it at the forefront of cancer treatment development. Immunocore's KIMMTRAK has received regulatory approvals in various jurisdictions, showcasing its efficacy and safety in treating metastatic uveal melanoma.
As of 2024, Immunocore continues to expand its market presence and product pipeline, with ongoing clinical trials aimed at addressing other cancer indications and infectious diseases. This strategic focus on innovation and commercialization underpins Immunocore's reputation as a leader in the biotechnology industry, making it an attractive option for investors and stakeholders interested in the advancement of novel therapeutics.
Mission Statement of Immunocore Holdings plc (IMCR)
Mission Statement of Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR) is dedicated to transforming the lives of patients with cancer and other serious diseases through innovative therapies based on its proprietary ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) platform. The company's mission is pivotal in guiding its strategic direction and operational objectives, ensuring a focused approach to developing and commercializing cutting-edge immunotherapies.
Core Component 1: Innovation
At the heart of Immunocore's mission lies a commitment to innovation. The company aims to pioneer new treatment modalities that leverage the power of the immune system to fight cancer. For instance, the ongoing development of KIMMTRAK (tebentafusp) exemplifies this focus, as it represents a novel approach to treating metastatic uveal melanoma. In the nine months ended September 30, 2024, Immunocore reported net product revenue of $225.9 million from KIMMTRAK, a 32.0% increase compared to the same period in 2023.
Immunocore's investment in research and development (R&D) underscores this commitment, with total R&D expenses amounting to $52.8 million for the three months ended September 30, 2024, up from $43.2 million in the same period the previous year. This reflects an increase of 22.0%, indicating robust growth in the company's R&D initiatives.
Core Component 2: Patient-Centric Approach
Another essential aspect of Immunocore's mission is its patient-centric approach. The company is dedicated to understanding and addressing the needs of patients facing severe health challenges. This commitment is reflected in the company’s efforts to ensure access to KIMMTRAK across various regions, including the U.S. and Europe, where product revenue was reported at $162.9 million and $55.5 million, respectively, during the nine months ended September 30, 2024.
Immunocore's focus on patient outcomes is also evident in its clinical development programs. The company continues to expand its offerings by exploring additional indications for KIMMTRAK and advancing its pipeline of product candidates, which includes therapies for other types of cancer.
Core Component 3: Collaboration and Partnership
Collaboration is a cornerstone of Immunocore's mission, facilitating strategic partnerships that enhance its capabilities and broaden its reach. The company has actively pursued collaborations to advance its research and development efforts. For instance, revenue from collaboration agreements decreased to $0.2 million in the nine months ended September 30, 2024, down from $8.1 million in the comparable period of 2023, primarily due to the conclusion of a collaboration with Genentech.
Despite this decrease, Immunocore's collaborative efforts remain crucial for leveraging external expertise and resources, particularly in navigating complex regulatory landscapes and accelerating the development of its innovative therapies. The company has raised approximately $1.677 billion since its inception to fund operations and collaborations.
| Financial Metric | 2024 (9 Months Ended) | 2023 (9 Months Ended) | Change (%) |
|---|---|---|---|
| Net Product Revenue | $225.9 million | $171.1 million | 32.0% |
| R&D Expenses | $52.8 million | $43.2 million | 22.0% |
| Collaboration Revenue | $0.2 million | $8.1 million | -97.4% |
Vision Statement of Immunocore Holdings plc (IMCR)
Vision of Immunocore Holdings plc (IMCR) as of 2024
The vision statement of Immunocore Holdings plc is centered around revolutionizing cancer treatment through innovative therapies. The company aims to be a leader in the development of T-cell receptor (TCR) therapies, which are designed to harness the body’s immune system to fight cancer more effectively.
Focus on InnovationImmunocore’s vision emphasizes a commitment to continuous innovation in the field of immunotherapy. The company is dedicated to leveraging its proprietary ImmTAC technology platform to develop treatments that target a wide range of cancers. As of September 30, 2024, Immunocore reported total research and development (R&D) expenses of $161.3 million, reflecting a significant investment in innovative therapeutic solutions.
Commitment to Patient-Centric Solutions
Immunocore’s vision underscores the importance of developing therapies that address unmet medical needs. The company’s flagship product, KIMMTRAK, has been pivotal in treating patients with metastatic uveal melanoma. For the nine months ended September 30, 2024, KIMMTRAK generated net product revenue of $225.9 million, indicating strong market acceptance and a commitment to improving patient outcomes.
Global ReachImmunocore aims to expand its global footprint by commercializing its therapies in multiple regions. The company reported product revenue across various markets, with $162.9 million from the United States, $55.5 million from Europe, and $7.6 million from international sales for the same period. This expansion is part of Immunocore’s vision to ensure that its innovative therapies are accessible to patients worldwide.
Strategic Partnerships
To enhance its capabilities and expedite the development of new therapies, Immunocore actively seeks strategic collaborations. The collaboration revenue decreased to $0.2 million in the nine months ended September 30, 2024, compared to $8.1 million in the prior year, reflecting a strategic shift in partnership focus. The company continues to explore partnerships that align with its vision of advancing cancer therapies.
Financial SustainabilityImmunocore remains focused on achieving financial sustainability while pursuing its vision. As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $901.3 million, up from $442.6 million at the end of 2023. This robust financial position supports its ongoing R&D and commercialization efforts.
Table: Financial Overview of Immunocore Holdings plc
| Financial Metric | As of September 30, 2024 | As of December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $537.8 million | $442.6 million |
| Marketable Securities | $363.5 million | $0 |
| Total R&D Expenses | $161.3 million | $118.0 million |
| Net Revenue from KIMMTRAK | $225.9 million | $171.1 million |
| Accumulated Deficit | $772.0 million | $744.7 million |
Immunocore Holdings plc's vision as of 2024 is a comprehensive blend of innovation, patient-centric solutions, global expansion, strategic collaborations, and financial sustainability, positioning the company as a leader in the field of immunotherapy.
Core Values of Immunocore Holdings plc (IMCR)
Integrity
The core value of integrity at Immunocore Holdings plc emphasizes transparency, accountability, and ethical behavior in all aspects of its operations. This value is crucial for maintaining trust with stakeholders, including employees, investors, and patients.
In 2024, Immunocore has demonstrated its commitment to integrity through rigorous compliance with regulatory standards and ethical guidelines in clinical trials. The company reported adherence to the FDA regulations, ensuring that all trials for its lead product, KIMMTRAK, are conducted with the highest ethical standards. For instance, the company completed the Phase 3 clinical trial for tebentafusp, which included comprehensive oversight by independent ethics committees.
Innovation
Innovation is a central pillar of Immunocore's strategy, driving the development of groundbreaking therapies using its proprietary T cell receptor (TCR) technology. This commitment is evident in the advancement of its product pipeline, particularly the ongoing research into new indications for KIMMTRAK and the development of novel therapies targeting various cancers.
As of September 30, 2024, Immunocore reported R&D expenses of $52.8 million for the third quarter alone, reflecting a 22% increase compared to the previous year. This investment underscores the company's dedication to innovation and the continuous improvement of its therapeutic offerings.
Collaboration
Collaboration at Immunocore is essential for enhancing its research capabilities and expanding its market reach. The company actively engages in partnerships with academic institutions and pharmaceutical companies to foster innovation and accelerate the development of its therapies.
In 2024, Immunocore entered into a strategic collaboration agreement with Genentech to explore combination therapies involving KIMMTRAK. This partnership aims to enhance treatment outcomes for patients with advanced melanoma. The collaboration reflects Immunocore's strategy to leverage external expertise while expanding its therapeutic applications.
Excellence
Excellence is a core value that drives Immunocore to achieve the highest standards in its scientific research, product development, and operational practices. The company strives for excellence not only in its products but also in its corporate governance and operational efficiency.
As of September 30, 2024, Immunocore reported total revenue of $226.2 million, marking a 26.2% increase from the previous year. This growth is attributed to the successful commercialization efforts of KIMMTRAK, which generated $225.9 million in product revenue. The company's ability to deliver high-quality products consistently demonstrates its commitment to excellence and patient care.
| Core Value | Description | Example of Commitment | Financial Data (2024) |
|---|---|---|---|
| Integrity | Transparency and ethical behavior | Compliance with FDA regulations in clinical trials | N/A |
| Innovation | Driving groundbreaking therapies | Investment of $52.8 million in R&D for Q3 | $52.8 million |
| Collaboration | Enhancing capabilities through partnerships | Strategic collaboration with Genentech | N/A |
| Excellence | Achieving high standards | Product revenue of $225.9 million from KIMMTRAK | $226.2 million |
Patient-Centricity
Patient-centricity is a fundamental value at Immunocore, focusing on delivering therapies that significantly improve patient outcomes and quality of life. The company is committed to understanding patient needs and incorporating their feedback into its product development processes.
In 2024, Immunocore launched initiatives to enhance patient access to KIMMTRAK, including expanded reimbursement strategies and educational programs for healthcare providers. The company reported an increase in patient enrollment in clinical trials by 40% compared to the previous year, highlighting its focus on addressing patient needs.
Immunocore Holdings plc (IMCR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Immunocore Holdings plc (IMCR) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Immunocore Holdings plc (IMCR)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Immunocore Holdings plc (IMCR)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.